A comparison of polymerase chain reaction examination of cerebrospinal fluid and conventional cytology in the diagnosis of lymphomatous meningitis

Cancer

Volumn 77, Issue 3, 1996, Pages 543-548

  Rhodes, C Harker ^a   Glantz, Michael J ^b   Glantz, Lisa ^b   Lekos, Andrew ^b   Sorenson, George D ^a   Honsinger, Charles ^a   Levy, Norman B ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

cerebrospinal fluid; lymphoma; lymphomatous meningitis; polymerase chain reaction

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DNA; DOXORUBICIN; LOMUSTINE; METHOTREXATE; PACLITAXEL; PREDNISONE; T LYMPHOCYTE RECEPTOR; THIOTEPA; VINCRISTINE;

ARTICLE; B CELL LYMPHOMA; BRAIN LYMPHOMA; CEREBROSPINAL FLUID CYTOLOGY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTODIAGNOSIS; GENE REARRANGEMENT; GLIOBLASTOMA; HUMAN; IMMUNOGLOBULIN GENE; INTRATHECAL DRUG ADMINISTRATION; LYMPHOCYTOSIS; MENINGITIS; METASTASIS; MULTIINFARCT DEMENTIA; NEUROLOGIC DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEPTOR GENE; RETROSPECTIVE STUDY; SKULL IRRADIATION;

BASE SEQUENCE; CYTOLOGICAL TECHNIQUES; HUMANS; LYMPHOMA; MENINGITIS; MOLECULAR SEQUENCE DATA; RETROSPECTIVE STUDIES;

EID: 0030023668     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960201)77:3<543::AID-CNCR17>3.0.CO;2-4     Document Type: Article

References (32)

1. Glass JP, Melamed M, Chernik NL, Posner JB. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 1979;29:1369-75.
2. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982;49:759-72.
3. Rhodes CH, Honsinger C, Sorenson GD. Detection of tumor-derived DNA in cerebrospinal fluid. J Neuropathol Exp Neurol 1994;53(4):364-8.
4. Rhodes CH, Honsinger C, Sorenson GD. PCR-detection of tumor-derived p53 DNA in cerebrospinal fluid. Am J Clin Pathol 1995; 103(4):404-8.
5. Schatz DG, Oettinger MA, Schlissel MS. V(D)J recombination: molecular biology and regulation. Annu Rev Immunol 1992; 10(359):359-83.
6. Slack DN, McCarthy KP, Wiedemann LM, Sloane JP. Evaluation of sensitivity, specificity, and reproducibility of an optimized method for detecting clonal rearrangements of immunoglobulin and T-cell receptor genes in formalin-fixed, paraffin-embedded sections. Diagn Mol Pathol 1993;2(4): 223-32.
7. Yamada M, Hudson S, Tournay O, Bittenbender S, Shane SS, Lange B, et al. Detection of minimal disease in hematopoietic malignancies of the B-cell lineage by using third-complementarity-determining region (CDR-III)-specific probes. Proc Natl Acad Sci USA 1989;86(13):5123-7.
8. Segal GH, Jorgensen T, Masih AS, Braylan RC. Optimal primer selection for clonality assessment by polymerase chain reaction analysis: I. Low grade B-cell lymphoproliferative disorders of nonfollicular center cell type. Hum Pathol 1994;25(12):1269-75.
9. Kaplan JG, DeSouza TG, Farkash A, Shafran B, Pack D, Faroog R, et al. Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neuro-Oncol 1990;9:225-9.
10. Schold SC, Wasserstrom WR, Fleisher M, Schwartz MK, Posner JB. Cerebrospinal fluid biochemical markers of central nervous system metastases. Ann Neurol 1980;8:597-604.
11. Wasserstrom WR, Schwartz MK, Fleisher M, Posner JB. Cerebrospinal fluid biochemical markers in central nervous system tumors: a review. Ann Clin Lab Science 1981;11:239-51.
12. Bach F, Bjerregaard B, Sölétormos G, Bach FW, Horn T. Diagnostic value of cerebrospinal fluid cytology in comparison with tumor marker activity in central nervous system metastases secondary to breast cancer. Cancer 1993;72: 2376-82.
13. van Zanten AP, Twijnstra A, de Visser BWO, van Heerde P, Hart AAM, Nooyen WJ. Cerebrospional fluid tumour markers in patients treated for meningeal malignancy. J Neurol Neurosurg Psychiatry 1991;54:119-23.
14. Koskiniemi M. Malignancy markers in the cerebrospinal fluid. Eur J Pediatr 1988;148:3-8.
15. Bigner SH, Johnston W. Cytopathology of the central nervous system. Chicago: American Society of Clinical Pathologists, 1994.
16. Vick WW, Wikstrand CJ, Bullard DE, Kemshead J, Coakham H, Schlom J et al. The use of a panel of monoclonal antibodies in the evaluation of cytologic specimens from the central nervous system. Acta Cytol 1987;31:815-24.
17. Bigner SH. Cerebrospinal fluid (CSF) cytology: current status and diagnostic applications. J Neuropathol Exp Neurol 1992;51(3):235-45.
18. Sze G, Soletsky S, Bronen R, Krol G. MR imaging of the cranial meninges with emphasis on contrast enhancement and meningeal carcinomatosis. Am J Neuroradiol 1989;10:965-75.
19. Chamberlain MC, Sandy AD, Press GA. Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology 1990;40:435-8.
20. Rogers LR, Duchesneau PM, Nunez C, Fishleder AJ, Weick JK, Bauer LJ, et al. Comparison of cisternal and lumbar CSF examination in leptomeningeal metastasis. Neurology 1992;42:1239-41.
21. Bleyer WA, Byme TN. Leptomeningeal cancer in leukemia and solid tumors. Curr Probl Cancer 1988;12:181-238.
22. Mackintosh FR, Colby TV, Podolsky WJ, Burke JS, Hoppe RT, Rosenfelt FD, et al. Central nervous system involvement in non-Hodgkin's lymphoma: an analysis of 105 cases. Cancer 1982;49:586-95
23. Hochberg FH, Miller DC. Primary central nervous system lymphoma. J Neurosurg 1988;68:835-53.
24. DeAngelis LM, Yahalom J, Heinemann M-H, Cirrincione C, Thaler HT, Krol G. Primary CNS lymphoma: combined treatment with chemotherapy and radiotherapy. Neurology 1990;40:80-6
25. DeAngelis LM, Yahalom J, Thaler HT, Kher U. Combined modality therapy for primary CNS lymphoma. J Clin Oncol 1992;10:635-43.
26. Selch MT, Shimizu KT, de Salles AF, Sutton C, Parker RG. Primary central nervous system lymphoma. Results at the University of California at Los Angeles and review of the literature. Am J Clin Oncol 1994;17(4):286-93.
27. Yamada M, Wasserman R, Lange B, Reichard BA, Womer RB, Rovera G. Minimal residual disease in childhood B-lineage lymphoblastic leukemia. Persistence of leukemic cells during the first 18 months of treatment. N Engl J Med 1990;323(7):448-55.
28. Segal GH, Jorgensen T, Scott M, Braylan RC. Optimal primer selection for clonality assessment by polymerase chain reaction analysis: II. Follicular lymphomas. Hum Pathol 1994;25(12):1276-82.
29. Diss TC, Peng H, Wotherspoon AC, Isaacson PG, Pan L. Detection of monoclonality in low-grade B-cell lymphomas using the polymerase chain reaction is dependent on primer selection and lymphoma type. J Pathol 1993; 169(3):291-5.
30. Inghirami G, Szabolcs MJ, Yee HT, Corradini P, Cesarman E, Knowles DM. Detection of Immunoglobulin gene rearrangement of B cell non-Hodgkin's lymphomas and leukemias in fresh, unfixed and formalin-fixed, paraffin-embedded tissue by polymerase chain reaction. Lab Invest 1993;68(6):746-57.
31. Reed TJ, Reid A, Wallberg K, O'Leary TJ, Frizzera G. Determination of B-cell clonality in paraffin-embedded lymph nodes using the polymerase chain reaction. Diagn Mol Pathol 1993;2(1):42-9.
32. O'Neill BP, Illig JJ. Primary central nervous system lymphoma. Mayo Clin Proc 1989;64:1005-20.